Antithymocyte immunoglobulin (rabbit)

Generic Name: Antithymocyte immunoglobulin (rabbit)

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 308067-60-9

Unique Ingredient Identifier: D7RD81HE4W

Background: Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin is via selective depletion of T-cells.

Indication: For prevention of renal transplant rejection

Associated Conditions: Rejection Acute Renal

Associated Therapies: -

Clinical Trials

Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic Transplantation

Phase 2

Terminated

Conditions: Myelodysplastic Syndromes
Acute Myeloid Leukemia

Interventions: Drug: Clofarabine
Drug: Cytarabine
Drug: Thymoglobulin
Procedure: Stem cell infusion

First Posted Date: 2008-01-15

Last Posted Date: 2014-09-12

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 7

Registration Number: NCT00593645

Locations: 🇺🇸
Ravi Vij, M.D., St. Louis, Missouri, United States

Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies

First Posted Date: 2007-12-03

Last Posted Date: 2020-04-14

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 73

Registration Number: NCT00566696

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

A Study of Thymoglobulin and Tacrolimus in Liver Transplant

Phase 4

Conditions: Liver Transplantation
Liver Disease
Immunosuppression

Interventions: Drug: tacrolimus
Drug: anti-thymocyte globulin (rabbit)

First Posted Date: 2007-11-28

Last Posted Date: 2007-11-28

Lead Sponsor: University of Nebraska

Target Recruit Count: 100

Registration Number: NCT00564538

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Relapsed Or Refractory Multiple Myeloma

Interventions: Drug: thymoglobulin

First Posted Date: 2007-10-17

Last Posted Date: 2013-04-23

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 6

Registration Number: NCT00545519

Locations: 🇺🇸
Washington Unvierstiy in St. Louis, St. Louis, Missouri, United States

Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor

Phase 2

Terminated

Conditions: Breast Cancer
Ovarian Cancer

Interventions: Drug: Bevacizumab
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Fludarabine
Drug: Melphalan
Drug: Thymoglobulin

First Posted Date: 2007-09-03

Last Posted Date: 2013-01-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 5

Registration Number: NCT00523809

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)

Phase 2

Terminated

Conditions: Hematological Malignancies
Leukemia
Myelodysplastic Syndrome
Lymphoma

Interventions: Drug: Mycophenolate Mofetil (MMF)
Drug: Thymoglobulin
Drug: Sirolimus
Procedure: Stem Cell Transplant

First Posted Date: 2007-07-25

Last Posted Date: 2020-09-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 13

Registration Number: NCT00506948

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma

Phase 2

Completed

Conditions: Disorder Related to Bone Marrow Transplantation
Lymphoma

Interventions: Drug: Fludarabine
Drug: Melphalan
Procedure: Allogeneic Transplant
Drug: Thymoglobulin

First Posted Date: 2007-07-25

Last Posted Date: 2020-12-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 33

Registration Number: NCT00506129

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Thymoglobulin and Total Lymphoid Irradiation for Hematologic Malignancies

Not Applicable

Completed

Conditions: Lymphoma
Leukemia

Interventions: Drug: Thymoglobulin
Radiation: Total Lymphoid Irradiation
Procedure: Peripheral Blood Stem Cell Infusion
Drug: Rituximab

First Posted Date: 2007-05-21

Last Posted Date: 2012-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT00476229

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Rabbit Antithymocyte Globulin (Thymoglobuline) With Ciclosporin for Patients With Acquired Aplastic Anaemia

Phase 2

Completed

Conditions: Aplastic Anemia

Interventions: Drug: rabbit antithymocyte globulin

First Posted Date: 2007-05-10

Last Posted Date: 2023-09-26

Lead Sponsor: European Society for Blood and Marrow Transplantation

Target Recruit Count: 35

Registration Number: NCT00471848

Locations: 🇫🇷
Henri Mondor Hospital, Creteil, France
🇸🇦
King Faisal Specialist Hospital & Research Cnetre, Riyadh, Saudi Arabia
🇬🇧
King's College Hospital, London, United Kingdom

and more 11 locations

A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation

Phase 2

Completed

Conditions: Disorder Related to Renal Transplantation

Interventions: Drug: Thymoglobulin
Drug: Belatacept
Drug: Tacrolimus
Drug: Mycophenolate Mofetil (MMF)
Drug: Sirolimus

First Posted Date: 2007-04-02

Last Posted Date: 2014-06-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 93

Registration Number: NCT00455013

Locations: 🇺🇸
Northwestern University Feinberg School Of Medicine, Chicago, Illinois, United States
🇺🇸
Denver Nephrology, Pc, Denver, Colorado, United States
🇺🇸
University Of Colorado Health Sciences Center, Denver, Colorado, United States

and more 9 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy